| Literature DB >> 17055323 |
Thanh G N Ton1, Susan R Heckbert, W T Longstreth, Mary Anne Rossing, Walter A Kukull, Gary M Franklin, Phillip D Swanson, Terri Smith-Weller, Harvey Checkoway.
Abstract
We investigated the risk of Parkinson's disease (PD) associated with calcium channel blockers (CCBs) and beta-blockers in a population-based case-control study of 206 men and women between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 controls without PD or other neurodegenerative disorders who were frequency matched on age, sex, duration of GHC enrollment and clinic. The adjusted odds ratio associated with ever use was 0.85 (95% confidence interval [CI]: 0.43, 1.66) for CCBs, and 1.20 (95% CI: 0.71, 2.03) for beta-blockers. We observed no association with PD risk for either class of medication in terms of duration, dose, number of prescriptions or pattern of use. The weakness of these associations and the absence of additional influence of dose or duration of use argue against any causal interpretation.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17055323 PMCID： PMC1893113 DOI： 10.1016/j.parkreldis.2006.08.011
Source DB: PubMed Journal: Parkinsonism Relat Disord ISSN： 1353-8020 Impact factor: 4.891